After a five day trial a federal jury in Delaware found that GILEAD Science Inc, did not infringe US patents with its HIV-prevention regimens using drugs Truvada and Descovy as the US Government had claimed. The Delaware jury found that the government patents were invalid. This was a huge blow to the government CDC and the FDA that were seeking over 1 billion in compensation for their role in the development of the HIV treatment and prevention drugs.